Prostate News and Research

RSS

New robotic surgical systems from El Camino Hospital

El Camino Hospital, the hospital of Silicon Valley, expands its minimally invasive surgical program to three da Vinci® Si HD Surgical Systems. Physicians performed more than 500 robotic surgeries over the past year and expect the number to increase in 2010 as more physicians undergo training with the enhanced equipment that allows for more minimally invasive procedures.

11 Nov 2009

Cancer screening methods are not perfect: Experts

In a recent New York Times article, the American Cancer Society (ACS) ignited a major controversy over the benefits of cancer screening, specifically with regards to their breast and prostate cancer guidelines. In the article, Dr. Otis Brawley, chief medical officer of the ACS, responded to a study in the current issue of the Journal of the American Medical Association.

11 Nov 2009

Prostate size growth not necessarily a predictor of development of cancer

New Mayo Clinic research studied the association between prostate-specific antigen (PSA) levels and prostate size and found that routine annual evaluation of prostate growth is not necessarily a predictor for the development of prostate cancer. However the study suggests that if a man's PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer.

11 Nov 2009

Researchers find link between two genes involved in cancer formation in humans

Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment.

11 Nov 2009

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

11 Nov 2009

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Microbix Biosystems Inc. today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide.

11 Nov 2009

Aduro BioTech raises funds through its Series A-1 financing

Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing.

10 Nov 2009

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.

10 Nov 2009

Prostatitis is a psychoneuromuscular condition: Study

In the November 2009 issue of the Journal of Urology, Stanford Medical School researcher Dr. Rodney Anderson and researchers at the National Center for Pelvic Pain Research, in a new study, demonstrated a high correlation between the location of painful trigger points inside the pelvic floor muscles of men with chronic prostatitis and the location in the body where they routinely complain of pain.

10 Nov 2009

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer.

9 Nov 2009

Chicago Prostate Cancer Center offers free prostate cancer guide

Prostate cancer is the second most common cancer in American men. One in six men will be diagnosed during his lifetime, according to the American Cancer Society.

9 Nov 2009

GTx reports financial results for the third quarter of 2009

GTx, Inc. today reported financial results for the third quarter of 2009. The net loss for the third quarter and nine months ended September 30, 2009 was $12.8 million and $35.4 million, respectively, compared with a net loss of $11.9 million and $37.9 million for the same periods in 2008. At September 30, 2009 GTx had cash, cash equivalents and short-term investments of $55.5 million.

9 Nov 2009

Chinese SFDA approves China Medical Technologies' Leukemia BCR/ABL fusion gene detection FISH Probe

China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its Leukemia BCR/ABL fusion gene detection FISH Probe (the "Leukemia BCR/ABL FISH Probe") from the State Food and Drug Administration of China (the "SFDA").

9 Nov 2009

Webinar: Latest updates on percutaneous and transcatheter treatment of liver, kidney and lung tumor ablation

Registration is now open for the Society of Interventional Radiology's "Image-guided Interventional Oncology (IO) Therapies" Webinar, which will provide the latest updates on percutaneous and transcatheter treatment of liver tumors, kidney tumor ablation and lung tumor ablation.

7 Nov 2009

Current health care debate in the United States complicated

The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated.

7 Nov 2009

Elevated PSA levels in men are not necessarily a predictor of the need for a prostate biopsy: Study

Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy.

7 Nov 2009

New findings may lead to novel therapeutic approaches for HIV and prostate cancer

New Haven, Conn.-Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases.

6 Nov 2009

Unum enhances the wellness benefit of its critical illness products by adding H1N1 vaccine

Unum has enhanced the wellness benefit of its critical illness products by adding the H1N1 vaccine to the list of qualifying procedures.

6 Nov 2009

Changes in PSA over time aid prostate cancer detection

The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection.

6 Nov 2009

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.

5 Nov 2009

Prostate News and Research

New robotic surgical systems from El Camino Hospital

Cancer screening methods are not perfect: Experts

Prostate size growth not necessarily a predictor of development of cancer

Researchers find link between two genes involved in cancer formation in humans

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Aduro BioTech raises funds through its Series A-1 financing

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Prostatitis is a psychoneuromuscular condition: Study

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Chicago Prostate Cancer Center offers free prostate cancer guide

GTx reports financial results for the third quarter of 2009

Chinese SFDA approves China Medical Technologies' Leukemia BCR/ABL fusion gene detection FISH Probe

Webinar: Latest updates on percutaneous and transcatheter treatment of liver, kidney and lung tumor ablation

Current health care debate in the United States complicated

Elevated PSA levels in men are not necessarily a predictor of the need for a prostate biopsy: Study

New findings may lead to novel therapeutic approaches for HIV and prostate cancer

Unum enhances the wellness benefit of its critical illness products by adding H1N1 vaccine

Changes in PSA over time aid prostate cancer detection

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News